Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZDCS0)

• Drug Name: Bezafibrate Drug Info
• Synonyms: Azufibrat; Befibrat; Befizal; BezaLande; BezaPuren; Bezabeta; Bezacur; Bezafibrat; Bezafibrato; Bezafibratum; Bezafisal;Bezalip; Bezamerck; Bezatol; Cedur; Difaterol; Durabezur; Eulitop; Lipox; Reducterol; Sklerofibrat; Solibay; Azupharma Brand of Bezafibrate; Bayer Brand of Bezafibrate; Berlin Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza Lande; Beza Puren; Bezafibrat PB; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; Bezafibrato [Spanish]; Bezalip Retard; Bezatol SR; Boehringer Mannheim Brand of Bezafibrate; Cryopharma Brand of Bezafibrate; Elfar Brand of Bezafibrate;Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Merckle Brand of Bezafibrate; Regadrin B; Roche Brand of Bezafibrate; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; BM 15075; LO 44; BF-759; BM 15.075; BM-15075; BM15.075; Berlin-Chemie Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezafibrate Berlin-Chemie Brand; Bezafibrato [INN-Spanish]; Bezafibratum [INN-Latin]; Bezalip (TN); Bezatol SR (TN); PB, Bezafibrat; BM-15.075; Bezafibrate (JP15/USAN/INN); Bezafibrate [USAN:BAN:INN:JAN]; A-[4-(4-chlorobenzoylaminoethyl)phenoxy]isobutyric acid; 2-(4-{2-[(4-chlorobenzoyl)amino]ethyl}phenoxy)-2-methylpropanoic acid; 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid; 2-[4-(2-[4-Chlorobenzamido]ethyl)-phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid; 2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]isobutyric Acid; 2-[4-[2-[(4-chlorobenzoyl)amino]ethyl]phenoxy]-2-methylpropanoic acid

Indication

Disease Entry	ICD 11	Status	REF
Hypercholesterolaemia	5C80.0	Approved	[1]
Hyperlipidaemia	5C80	Approved	[2]
Hyperlipidemia	5C80.Z	Approved	[3]

• Therapeutic Class: Antilipemic Agents
• Cross-matching ID:
  PubChem CID: 39042
  ChEBI ID: CHEBI:47612
  CAS Number: CAS 41859-67-0
  TTD Drug ID: DMZDCS0
  VARIDT Drug ID: DR00491
  INTEDE Drug ID: DR0209

Molecule-Related Drug Atlas

Drug(s) Targeting Peroxisome proliferator-activated receptor alpha (PPARA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lobeglitazone	DMHY3IP	Type-2 diabetes	5A11	Approved	[16]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[17]
Ciprofibrate	DMGC5DB	Hyperlipoproteinemia	5C80	Approved	[17]
Pemafibrate	DMD1VZL	Hyperlipidemia	5C80.Z	Approved	[18]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[19]
Ragaglitazar	DMFSHEM	Type-1 diabetes	5A10	Phase 3	[20]
CS-038	DM67P0F	Type-2 diabetes	5A11	Phase 3	[21]
TESAGLITAZAR	DMGRBN5	Type-1 diabetes	5A10	Phase 3	[22]
GFT-505	DM7ZOAE	Non-alcoholic steatohepatitis	DB92.1	Phase 3	[23]
ZYH-1	DMMBJYC	Lipid metabolism disorder	5C52.Z	Phase 3	[24]

Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[25]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[26]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[27]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[28]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[29]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[30]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[31]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[32]
Prasterone	DM67VKL	Chronic obstructive pulmonary disease	CA22	Approved	[26]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[33]

Drug(s) Affected By 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[34]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[35]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[36]
Digoxin	DMQCTIH	Arrhythmia	BC9Z	Approved	[37]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[38]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[41]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[43]

Drug(s) Affected By Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[37]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[45]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[46]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[47]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Procaine	DM4LSNE	Anaesthesia	9A78.6	Approved	[49]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[50]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[51]
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[52]

Drug(s) Affected By Superoxide dismutase (SOD1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[53]
Haloperidol	DM96SE0	Delirium		Approved	[37]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[54]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[55]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[56]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[57]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[58]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[59]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[60]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[61]

Drug(s) Affected By Cytochrome b-245 light chain (CYBA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[62]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[63]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[65]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[66]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[68]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]

Drug(s) Affected By Peroxisome proliferator-activated receptor delta (PPARD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[71]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[72]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[75]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[76]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[77]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[78]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[81]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[82]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[83]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[84]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[85]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[86]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[87]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[88]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[89]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[90]

Drug(s) Affected By Tumor necrosis factor receptor superfamily member 6 (FAS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[54]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[38]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[91]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[92]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[93]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[95]
Fructose	DM43AN2	Vomiting	MD90	Approved	[96]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[54]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[97]

Drug(s) Affected By Cytochrome P450 4A11 (CYP4A11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[98]
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[99]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[99]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[100]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[99]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[99]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[99]

Drug(s) Affected By Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[101]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[102]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[103]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[104]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[103]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[105]
Bifonazole	DM3KN7V	Fungal infection	1F29-1F2F	Approved	[106]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[107]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[103]

Drug(s) Affected By Cytochrome P450 2C8 (CYP2C8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[108]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[109]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[108]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[109]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[110]
Loratadine	DMF3AN7	Allergy	4A80-4A85	Approved	[108]
Zafirlukast	DMHNQOG	Asthma	CA23	Approved	[108]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[108]
Sorafenib	DMS8IFC	Adenocarcinoma	2D40	Approved	[111]
Dabrafenib	DMX6OE3	Melanoma	2C30	Approved	[112]

Drug(s) Affected By Bifunctional epoxide hydrolase 2 (EPHX2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[86]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[115]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[117]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[117]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[118]

Drug(s) Affected By Cytochrome P450 2J2 (CYP2J2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[119]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[120]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[121]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[122]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[119]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[119]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[117]

Drug(s) Affected By Protein SCO2 homolog, mitochondrial (SCO2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[124]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[124]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[125]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[126]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[127]
Urethane	DM7NSI0	N. A.	N. A.	Phase 4	[128]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[129]

Drug(s) Affected By Nephrin (NPHS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[130]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[131]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[132]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[133]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[134]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[135]
PIRINIXIC ACID	DM82Y75	Pulmonary fibrosis	CB03.4	Preclinical	[136]
Puromycin	DMDKLB5	N. A.	N. A.	Preclinical	[137]
bisphenol A	DM2ZLD7	Discovery agent	N.A.	Investigative	[138]

Drug(s) Affected By Bile salt export pump (ABCB11)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[139]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[140]
Glipizide	DMZA5PQ	Diabetic complication	5A2Y	Approved	[140]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[141]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[139]
Ofloxacin	DM0VQN3	Acute gonococcal cervicitis		Approved	[140]
Primidone	DM0WX6I	Epilepsy	8A60-8A68	Approved	[142]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[139]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[143]
Nitrendipine	DM21C09	Hypertension	BA00-BA04	Approved	[139]

Drug(s) Affected By Phospholipid-transporting ATPase ABCA1 (ABCA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[144]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[145]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[41]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[146]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[147]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[148]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[149]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[150]

Drug(s) Affected By Insulin (INS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tolbutamide	DM02AWV	Advanced cancer	2A00-2F9Z	Approved	[151]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[152]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[153]
Fructose	DM43AN2	Vomiting	MD90	Approved	[154]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[155]
Glimepiride	DM5FSJA	Diabetic complication	5A2Y	Approved	[156]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[157]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[158]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[159]

Drug(s) Affected By Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indomethacin	DMSC4A7	Bursitis		Approved	[160]
Amphotericin B	DMTAJQE	Acne vulgaris	ED80	Approved	[161]
Fructose	DM43AN2	Vomiting	MD90	Approved	[37]
Ketoprofen	DMRKXPT	Bursitis		Approved	[37]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[162]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[163]
Baclofen	DM0QV1J	Multiple sclerosis	8A40	Approved	[164]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[165]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[166]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[167]

Drug(s) Affected By Apolipoprotein A-I (APOA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[168]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[169]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[170]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[171]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[172]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[173]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[174]

Drug(s) Affected By Apolipoprotein E (APOE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[175]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[176]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[177]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[178]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[179]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]

Drug(s) Affected By Apolipoprotein A-II (APOA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[180]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[181]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[173]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[182]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[181]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[173]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[181]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[126]

Drug(s) Affected By Apolipoprotein C-III (APOC3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[183]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[183]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[183]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[182]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[184]

Drug(s) Affected By C-reactive protein (CRP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lidocaine	DML4ZOT	Anaesthesia	9A78.6	Approved	[37]
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[185]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[186]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[187]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Acalabrutinib	DM7GCVW	leukaemia	2A60-2B33	Approved	[188]
Penicillamine	DM40EF6	Cystinuria	5C60.2	Approved	[189]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[190]
Tibolone	DM78XFG	Anabolic metabolism	5C50-5C8Z	Approved	[191]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[67]

Drug(s) Affected By Apolipoprotein B-100 (APOB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[183]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[183]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[192]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[183]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[193]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[183]
Aluminium	DM6ECN9	Hyperhidrosis	EE00	Approved	[194]

Drug(s) Affected By Insulin-like growth factor I (IGF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dantrolene	DM1D8XY	Hyperthermia	MG26	Approved	[195]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[167]
Methimazole	DM25FL8	Hyperthyroidism	5A02	Approved	[39]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[196]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[100]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[100]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[197]
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[198]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[199]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[200]

Drug(s) Affected By Plasminogen activator inhibitor 1 (SERPINE1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[201]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[202]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[203]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[204]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[205]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[206]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[207]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[208]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[115]

Drug(s) Affected By Endothelin-1 (EDN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[209]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[211]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[212]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[213]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[214]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[215]
Cyclophosphamide	DM4O2Z7	Advanced cancer	2A00-2F9Z	Approved	[216]
Lisinopril	DMUOK4C	Chronic heart failure	BD1Z	Approved	[217]

Drug(s) Affected By Fatty acid-binding protein, heart (FABP3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[41]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[218]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[219]
Haloperidol	DM96SE0	Delirium		Approved	[220]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[210]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[182]
Ifosfamide	DMCT3I8	Adult central nervous system germ cell tumor		Approved	[221]
Benzatropine	DMF7EXL	Parkinsonian disorder		Approved	[220]
Sodium lauryl sulfate	DMLJ634	Constipation	DD91.1	Approved	[222]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[223]

Drug(s) Affected By Lipoprotein lipase (LPL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[37]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[104]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[167]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[224]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[225]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[227]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[228]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[227]

Drug(s) Affected By Fatty acid-binding protein, liver (FABP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[229]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Citalopram	DM2G9AE	Acute coronary syndrome	BA41	Approved	[230]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[229]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[229]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Fluoxetine	DM3PD2C	Bipolar depression		Approved	[229]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[231]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[232]

Drug(s) Affected By Choriogonadotropin subunit beta 3 (CGB3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[233]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[234]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[235]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[236]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[235]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[237]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[238]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[239]

Drug(s) Affected By Osteopontin (SPP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[45]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[104]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[240]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[241]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[94]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[242]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[64]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[243]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[219]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[244]

Drug(s) Affected By Hepatic triacylglycerol lipase (LIPC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[245]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[246]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[247]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[126]
Arsenic	DMTL2Y1	N. A.	N. A.	Approved	[248]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[249]

Drug(s) Affected By Cholesteryl ester transfer protein (CETP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[250]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[251]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[252]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[172]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[251]
Alitretinoin	DMME8LH	Kaposi sarcoma	2B57	Approved	[253]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[251]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[135]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[254]

Drug(s) Affected By Fatty acid-binding protein, adipocyte (FABP4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[255]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[256]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[257]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[258]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[255]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Ursodeoxycholic acid	DMCUT21	Cholelithiasis	DC11	Approved	[259]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[146]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[260]

Drug(s) Affected By Platelet glycoprotein 4 (CD36)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[183]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[261]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[245]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[262]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[263]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[264]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[68]
Disulfiram	DMCL2OK	Alcohol dependence	6C40.2	Approved	[265]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Asasantin	DMCZIHT	Cerebrovascular ischaemia	8B1Z	Approved	[266]

Drug(s) Affected By Retinoic acid receptor RXR-alpha (RXRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[267]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
Selenium	DM25CGV	N. A.	N. A.	Approved	[268]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[269]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[270]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[271]
Acitretin	DM8BKU9	Psoriasis vulgaris	EA90	Approved	[272]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[221]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[273]

Drug(s) Affected By Phosphatidylcholine translocator ABCB4 (ABCB4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[274]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[275]
Methysergide	DM1EF73	Migraine	8A80	Approved	[142]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[276]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[277]
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[142]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[231]
Omeprazole	DM471KJ	Cystic fibrosis	CA25	Approved	[278]

Drug(s) Affected By Cytochrome P450 7A1 (CYP7A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Calcipotriol	DM03CP7	Psoriasis	EA90	Approved	[279]
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[276]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[277]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[280]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[281]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[86]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[282]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[208]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[283]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[280]

Drug(s) Affected By Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[284]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[285]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[245]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[246]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[125]

Drug(s) Affected By Retinoic acid receptor RXR-beta (RXRB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[286]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[116]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[69]
Lindane	DMB8CNL	Infestations of lice and scabies	1G00.Z	Approved	[287]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[182]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[288]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[267]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[289]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[267]
Decitabine	DMQL8XJ	Acute myelogenous leukaemia	2A41	Approved	[290]

Drug(s) Affected By CD40 ligand (CD40LG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[167]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[291]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[262]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[292]
Asasantin	DMCZIHT	Cerebrovascular ischaemia	8B1Z	Approved	[266]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[293]
Menthol	DMG2KW7	Back pain	ME84.Z	Approved	[294]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[295]
Eptifibatide	DMQXTJS	Acute cardiac ischemic events	BA40.Z	Approved	[296]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[293]

Drug(s) Affected By Long-chain-fatty-acid--CoA ligase 1 (ACSL1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[297]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[113]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[219]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[298]
Tolcapone	DM8MNVO	Parkinson disease	8A00.0	Approved	[263]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[221]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[221]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[221]

Drug(s) Affected By Peroxisome proliferator-activated receptor gamma (PPARG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[299]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[46]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[300]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[256]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[301]
Isoniazid	DM5JVS3	Latent tuberculosis infection		Approved	[302]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[95]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[303]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[304]

Drug(s) Affected By Leptin (LEP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[305]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[167]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[306]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[307]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[308]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[305]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[305]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[227]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[233]
Amlodipine	DMBDAZV	Angina pectoris	BA40	Approved	[309]

Drug(s) Affected By Tumor necrosis factor ligand superfamily member 6 (FASLG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[297]
Gefitinib	DM15F0X	Colon adenocarcinoma		Approved	[310]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[311]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[93]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[312]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[86]
Fructose	DM43AN2	Vomiting	MD90	Approved	[96]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[313]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[314]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[315]

Drug(s) Affected By Retinoic acid receptor RXR-gamma (RXRG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[297]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[316]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[317]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[318]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[267]
Bexarotene	DMOBIKY	Cutaneous T-cell lymphoma	2B01	Approved	[267]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[319]
Triclosan	DMZUR4N	Malaria	1F40-1F45	Approved	[133]
Fenretinide	DMRD5SP	Macular degeneration	9B78.3	Phase 3	[320]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[135]

Drug(s) Affected By Very long-chain specific acyl-CoA dehydrogenase, mitochondrial (ACADVL)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[220]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[321]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[246]
Haloperidol	DM96SE0	Delirium		Approved	[220]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[68]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[125]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[184]

Drug(s) Affected By Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[322]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[73]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[231]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[245]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[178]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[323]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[324]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[325]

Drug(s) Affected By Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[197]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[125]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[180]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[118]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[326]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[126]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]

Drug(s) Affected By Oxysterols receptor LXR-beta (NR1H2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[245]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[252]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[327]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[328]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[328]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[141]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[326]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[328]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[251]

Drug(s) Affected By Phospholipid transfer protein (PLTP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[329]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Isotretinoin	DM4QTBN	Acne vulgaris	ED80	Approved	[246]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[226]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[330]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[182]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[326]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[237]

Drug(s) Affected By Sterol regulatory element-binding protein 2 (SREBF2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[37]
Selenium	DM25CGV	N. A.	N. A.	Approved	[114]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[331]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[74]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[332]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[199]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[327]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[333]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[68]

Drug(s) Affected By Oxysterols receptor LXR-alpha (NR1H3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[257]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[328]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[334]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[328]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[335]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[141]
Temozolomide	DMKECZD	Adenocarcinoma	2D40	Approved	[326]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[336]

Drug(s) Affected By Peroxisomal acyl-coenzyme A oxidase 1 (ACOX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[42]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[245]
Testosterone	DM7HUNW	Hot flushes	GA30	Approved	[67]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[80]
Ivermectin	DMDBX5F	Intestinal strongyloidiasis due to nematode parasite	1F6B	Approved	[125]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[184]
Ciprofibrate	DMGC5DB	Hyperlipoproteinemia	5C80	Approved	[337]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[260]
Sodium Acetate Anhydrous	DMH21E0	Hyponatraemia	5C72	Approved	[338]

Drug(s) Affected By Adiponectin (ADIPOQ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indinavir	DM0T3YH	Human immunodeficiency virus infection	1C62	Approved	[305]
Ritonavir	DMU764S	Human immunodeficiency virus infection	1C62	Approved	[305]
Ramipril	DM2R68E	Acute heart failure	BD10-BD13	Approved	[339]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[340]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[305]
Cilazapril	DM4V6JA	Congestive heart failure	BD10	Approved	[341]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[342]
Stavudine	DM6DEK9	Human immunodeficiency virus infection	1C62	Approved	[305]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[227]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[77]

Drug(s) Affected By kinase isozyme 4, mitochondrial (PDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[316]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[343]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[344]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[324]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[221]
Clodronate	DM9Y6X7	Hypercalcaemia	5B91.0	Approved	[221]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[221]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Testosterone enanthate	DMB6871	N. A.	N. A.	Approved	[69]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[182]

Drug(s) Affected By Proprotein convertase subtilisin/kexin type 9 (PCSK9)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[180]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[345]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[182]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[8]
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[118]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[346]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[347]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[126]

Drug(s) Affected By ATP-binding cassette sub-family C member 2 (ABCC2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lopinavir	DMITQS0	Human immunodeficiency virus infection	1C62	Approved	[348]
Sulfinpyrazone	DMEV954	Gout	FA25	Approved	[349]
Probenecid	DMMFWOJ	Acute gonococcal cervicitis		Approved	[350]
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[351]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[352]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[353]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[354]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[355]
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[356]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[44]

Drug(s) Affected By Achaete-scute homolog 2 (ASCL2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[357]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[126]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[358]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[134]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[135]
LINOLEIC ACID	DMDGPY9	Discovery agent	N.A.	Investigative	[7]

Drug(s) Affected By ATP-binding cassette sub-family G member 5 (ABCG5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Clavulanate	DM2FGRT	Bacteremia	1A73	Approved	[276]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[354]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[40]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[148]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[354]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[116]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[141]
Cupric Sulfate	DMP0NFQ	Fungal infection	1F29-1F2F	Approved	[126]

Drug(s) Affected By Fibroblast growth factor 21 (FGF21)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[70]
Fenofibrate	DMFKXDY	Coronary atherosclerosis		Approved	[359]
Rosiglitazone	DMILWZR	Chronic kidney disease	GB61	Approved	[360]
Pioglitazone	DMKJ485	Amyotrophic lateral sclerosis	8B60.0	Approved	[360]
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[361]
Famotidine	DMRL3AB	Gastric ulcer	DA60	Approved	[362]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[363]
Lansoprazole	DMXYLQ3	Gastric ulcer	DA60	Approved	[362]
Resveratrol	DM3RWXL	Giant cell arteritis	4A44.2	Phase 3	[364]

Drug(s) Affected By ATP-binding cassette sub-family C member 4 (ABCC4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[352]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[365]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[366]
Glutathione	DMAHMT9	Human immunodeficiency virus infection	1C62	Approved	[367]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[48]
Nefazodone	DM4ZS8M	Major depressive disorder	6A70.3	Approved	[208]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[368]
Aspirin	DM672AH	Acute coronary syndrome	BA41	Approved	[369]
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[79]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[123]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Peroxisome proliferator-activated receptor alpha (PPARA)	TTJ584C	PPARA_HUMAN	Agonist	[4]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[6]
Achaete-scute homolog 2 (ASCL2)	OT3D62WB	ASCL2_HUMAN	Gene/Protein Processing	[7]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Gene/Protein Processing	[8]
Aldehyde dehydrogenase family 3 member A2 (ALDH3A2)	OT714BUO	AL3A2_HUMAN	Gene/Protein Processing	[9]
Alkaline phosphatase, tissue-nonspecific isozyme (ALPL)	OTG7J4BP	PPBT_HUMAN	Gene/Protein Processing	[10]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Gene/Protein Processing	[11]
Apolipoprotein A-II (APOA2)	OTQ3HGTC	APOA2_HUMAN	Gene/Protein Processing	[12]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Gene/Protein Processing	[13]
Apolipoprotein C-III (APOC3)	OTW3520C	APOC3_HUMAN	Gene/Protein Processing	[14]
Apolipoprotein E (APOE)	OTFOWL2H	APOE_HUMAN	Gene/Protein Processing	[15]

References

• [1] Simvastatin and bezafibrate: effects on serum lipoproteins and lecithin: cholesterol acyltransferase activity in familial hypercholesterolaemia. Eur J Clin Pharmacol. 1988;35(6):579-83.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2668).
• [3] Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments. Int J Mol Sci. 2023 Sep 11;24(18):13942.
• [4] Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
• [5] Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet. 1998 Feb;34(2):155-62.
• [6] Effects of Bezafibrate on Hepatic Cholesterol Metabolism Eur J Clin Pharmacol. 1991;40 Suppl 1:S33-6.
• [7] Expression of cFABP and PPAR in trophoblast cells: effect of PPAR ligands on linoleic acid uptake and differentiation. Biochim Biophys Acta. 2005 Feb 21;1687(1-3):181-94. doi: 10.1016/j.bbalip.2004.11.017.
• [8] Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. Atherosclerosis. 2011 Jul;217(1):165-70. doi: 10.1016/j.atherosclerosis.2011.02.012. Epub 2011 Feb 22.
• [9] Bezafibrate induces FALDH in human fibroblasts; implications for Sj?gren-Larsson syndrome. Mol Genet Metab. 2006 Sep-Oct;89(1-2):111-5. doi: 10.1016/j.ymgme.2006.05.009. Epub 2006 Jul 11.
• [10] The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism. 1993 Jul;42(7):839-42.
• [11] Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element. J Biol Chem. 1994 Dec 9;269(49):31012-8.
• [12] Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients. Arzneimittelforschung. 1994 Nov;44(11):1217-22.
• [13] Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis. Nephrol Dial Transplant. 1992;7(7):623-6. doi: 10.1093/ndt/7.7.623.
• [14] The hypolipidemic action of bezafibrate therapy in hypertriglyceridemia is mediated by upregulation of lipoprotein lipase: no effects on VLDL substrate affinity to lipolysis or LDL receptor binding. Atherosclerosis. 2000 Dec;153(2):363-71. doi: 10.1016/s0021-9150(00)00409-3.
• [15] Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Am J Med. 1994 Jun 6;96(6A):55S-63S. doi: 10.1016/0002-9343(94)90233-x.
• [16] Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
• [17] Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
• [18] Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
• [19] Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
• [20] Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
• [21] Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
• [22] Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
• [23] Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
• [24] Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARalpha agonist with moderate PPARgamma agonist activity in healthy human subjects. Clin Drug Investig. 2013 Nov;33(11):809-16.
• [25] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [26] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [27] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [28] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [29] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [30] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [31] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [32] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [33] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [34] Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Delta24-reductase-deficient cell line. Biochem J. 2009 May 13;420(2):305-15.
• [35] Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
• [36] Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin. Circulation. 2008 Jul 22;118(4):355-62. doi: 10.1161/CIRCULATIONAHA.108.773267. Epub 2008 Jun 16.
• [37] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [38] Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
• [39] Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
• [40] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [41] Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023 Jun 29;13(1):10519. doi: 10.1038/s41598-023-37488-0.
• [42] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [43] PPAR gamma ligands, troglitazone and pioglitazone, up-regulate expression of HMG-CoA synthase and HMG-CoA reductase gene in THP-1 macrophages. FEBS Lett. 2002 Jun 5;520(1-3):177-81.
• [44] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [45] Investigation of in vitro odonto/osteogenic capacity of cannabidiol on human dental pulp cell. J Dent. 2021 Jun;109:103673. doi: 10.1016/j.jdent.2021.103673. Epub 2021 Apr 16.
• [46] Protective effects of myricitrin against osteoporosis via reducing reactive oxygen species and bone-resorbing cytokines. Toxicol Appl Pharmacol. 2014 Nov 1;280(3):550-60.
• [47] Hydroxychloroquine decreases human MSC-derived osteoblast differentiation and mineralization in vitro. J Cell Mol Med. 2018 Feb;22(2):873-882. doi: 10.1111/jcmm.13373. Epub 2017 Oct 3.
• [48] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [49] Sensitivity of human dental pulp cells to eighteen chemical agents used for endodontic treatments in dentistry. Odontology. 2013 Jan;101(1):43-51.
• [50] Glucosamine promotes osteogenic differentiation of dental pulp stem cells through modulating the level of the transforming growth factor-beta type I receptor. J Cell Physiol. 2010 Oct;225(1):140-51.
• [51] A highly potent 26,27-Hexafluoro-1a,25-dihydroxyvitamin D3 on calcification in SV40-transformed human fetal osteoblastic cells. Calcif Tissue Int. 2002 Jun;70(6):488-95.
• [52] Novel pathways of endocrine disruption through pesticides interference with human mineralocorticoid receptors. Toxicol Sci. 2018 Mar 1;162(1):53-63.
• [53] Poly(ADP-ribose) polymerase 1 contributes to oxidative stress through downregulation of sirtuin 3 during cisplatin nephrotoxicity. Anat Cell Biol. 2016 Sep;49(3):165-176. doi: 10.5115/acb.2016.49.3.165. Epub 2016 Sep 29.
• [54] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [55] Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor. Cancer Res. 2002 Aug 1;62(15):4419-26.
• [56] Gypenosides protect retinal pigment epithelium cells from oxidative stress. Food Chem Toxicol. 2018 Feb;112:76-85.
• [57] Inactivation of cytochrome c oxidase by mutant SOD1s in mouse motoneuronal NSC-34 cells is independent from copper availability but is because of nitric oxide. J Neurochem. 2010 Jan;112(1):183-92. doi: 10.1111/j.1471-4159.2009.06441.x. Epub 2009 Oct 20.
• [58] Impairment of mitochondrial anti-oxidant defence in SOD1-related motor neuron injury and amelioration by ebselen. Brain. 2006 Jul;129(Pt 7):1693-709. doi: 10.1093/brain/awl118. Epub 2006 May 15.
• [59] Development of an alternative zebrafish model for drug-induced intestinal toxicity. J Appl Toxicol. 2018 Feb;38(2):259-273. doi: 10.1002/jat.3520. Epub 2017 Oct 13.
• [60] Epinephrine upregulates superoxide dismutase in human coronary artery endothelial cells. Free Radic Biol Med. 2001 Jan 15;30(2):148-53.
• [61] Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther. 2005 Sep;4(9):949-55.
• [62] Rhizoma Dioscoreae Nipponicae polysaccharides protect HUVECs from H2O2-induced injury by regulating PPAR factor and the NADPH oxidase/ROS-NF-B signal pathway. Toxicol Lett. 2015 Jan 5;232(1):149-58. doi: 10.1016/j.toxlet.2014.10.006. Epub 2014 Oct 8.
• [63] The ligands/activators for peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma increase Cu2+,Zn2+-superoxide dismutase and decrease p22phox message expressions in primary endothelial cells. Metabolism. 2001 Jan;50(1):3-11.
• [64] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [65] Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression. Rheumatology (Oxford). 2008 Jan;47(1):31-5. doi: 10.1093/rheumatology/kem289.
• [66] Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4578-83.
• [67] The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
• [68] Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
• [69] Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
• [70] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [71] Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
• [72] Functional characterization of peroxisome proliferator-activated receptor-/ expression in colon cancer. Mol Carcinog. 2011 Nov;50(11):884-900. doi: 10.1002/mc.20757. Epub 2011 Mar 11.
• [73] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [74] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [75] Aspirin-induced apoptosis in jurkat cells is not mediated by peroxisome proliferator-activated receptor delta. Mol Cell Biochem. 2004 Nov;266(1-2):57-63. doi: 10.1023/b:mcbi.0000049138.67699.7b.
• [76] Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
• [77] (9)-Tetrahydrocannabinol upregulates fatty acid 2-hydroxylase (FA2H) via PPAR induction: A possible evidence for the cancellation of PPAR/-mediated inhibition of PPAR in MDA-MB-231?cells. Arch Biochem Biophys. 2019 Feb 15;662:219-225. doi: 10.1016/j.abb.2018.12.011. Epub 2018 Dec 13.
• [78] Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells. Anticancer Res. 2009 Sep;29(9):3647-58.
• [79] Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
• [80] Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
• [81] Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
• [82] Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
• [83] Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
• [84] Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
• [85] Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
• [86] Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
• [87] Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
• [88] Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
• [89] The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
• [90] Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
• [91] Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004 May 1;64(9):3022-9. doi: 10.1158/0008-5472.can-03-1880.
• [92] Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. Biol Chem. 2006 Dec;387(12):1629-33. doi: 10.1515/BC.2006.203.
• [93] Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000 Feb;45(3):788-94. doi: 10.1016/s0008-6363(99)00369-7.
• [94] Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
• [95] Regulatory role of KEAP1 and NRF2 in PPAR expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 2012 Aug 15;53(4):758-68. doi: 10.1016/j.freeradbiomed.2012.05.041. Epub 2012 Jun 7.
• [96] Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
• [97] Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
• [98] Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro. 2009 Oct;23(7):1259-67.
• [99] Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
• [100] Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
• [101] Aromatase inhibition: translation into a successful therapeutic approach. Clin Cancer Res. 2005 Apr 15;11(8):2809-21. doi: 10.1158/1078-0432.CCR-04-2187.
• [102] Cannabidiol (CBD) but not tetrahydrocannabinol (THC) dysregulate in vitro decidualization of human endometrial stromal cells by disruption of estrogen signaling. Reprod Toxicol. 2020 Apr;93:75-82. doi: 10.1016/j.reprotox.2020.01.003. Epub 2020 Jan 14.
• [103] Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
• [104] Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
• [105] Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase. J Med Chem. 2005 Mar 10;48(5):1563-75.
• [106] Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
• [107] Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol. 1999 Dec 31;71(5-6):223-30.
• [108] Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
• [109] Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
• [110] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [111] Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
• [112] Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy. Toxicol Appl Pharmacol. 2022 Jan 1;434:115797. doi: 10.1016/j.taap.2021.115797. Epub 2021 Nov 13.
• [113] Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
• [114] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [115] Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
• [116] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [117] Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner. Toxicol Appl Pharmacol. 2018 Sep 15;355:156-163.
• [118] Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
• [119] Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
• [120] In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver. Xenobiotica. 2003 Jun;33(6):615-23.
• [121] Differentiation-specific factors modulate epidermal CYP1-4 gene expression in human skin in response to retinoic acid and classic aryl hydrocarbon receptor ligands. J Pharmacol Exp Ther. 2006 Dec;319(3):1162-71.
• [122] Cytochrome P450 expression, induction and activity in human induced pluripotent stem cell-derived intestinal organoids and comparison with primary human intestinal epithelial cells and Caco-2 cells. Arch Toxicol. 2021 Mar;95(3):907-922. doi: 10.1007/s00204-020-02953-6. Epub 2020 Dec 2.
• [123] Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
• [124] Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018 Aug 9;9(1):3069. doi: 10.1038/s41467-018-05402-2.
• [125] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [126] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [127] Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 2015 Apr 16;234(2):139-50.
• [128] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [129] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [130] Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int. 2006 Jul;70(1):177-86. doi: 10.1038/sj.ki.5001515. Epub 2006 May 17.
• [131] Reversal of albuminuria by combined AM6545 and perindopril therapy in experimental diabetic nephropathy. Br J Pharmacol. 2018 Dec;175(23):4371-4385. doi: 10.1111/bph.14495. Epub 2018 Nov 6.
• [132] Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone. J Am Soc Nephrol. 2006 Jun;17(6):1624-32. doi: 10.1681/ASN.2005090983. Epub 2006 May 10.
• [133] Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
• [134] CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
• [135] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [136] PPARalpha activation upregulates nephrin expression in human embryonic kidney epithelial cells and podocytes by a dual mechanism. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1818-24. doi: 10.1016/j.bbrc.2005.10.158. Epub 2005 Nov 2.
• [137] Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol. 2001 May;158(5):1723-31. doi: 10.1016/S0002-9440(10)64128-4.
• [138] Bisphenol A Exposure Changes the Transcriptomic and Proteomic Dynamics of Human Retinoblastoma Y79 Cells. Genes (Basel). 2021 Feb 11;12(2):264. doi: 10.3390/genes12020264.
• [139] Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
• [140] Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
• [141] Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
• [142] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
• [143] A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
• [144] Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008 Dec;58(12):3675-83.
• [145] Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
• [146] Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
• [147] Proton pump inhibitor lansoprazole is a nuclear liver X receptor agonist. Biochem Pharmacol. 2010 May 1;79(9):1310-6. doi: 10.1016/j.bcp.2009.12.018. Epub 2010 Jan 8.
• [148] Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid. J Lipid Res. 2019 Apr;60(4):794-804. doi: 10.1194/jlr.M088880. Epub 2019 Feb 1.
• [149] Pregnane X receptor-agonists down-regulate hepatic ATP-binding cassette transporter A1 and scavenger receptor class B type I. Biochem Biophys Res Commun. 2005 Jun 17;331(4):1533-41. doi: 10.1016/j.bbrc.2005.04.071.
• [150] Inhibition of liver x receptor/retinoid X receptor-mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler Thromb Vasc Biol. 2010 Jun;30(6):1228-36. doi: 10.1161/ATVBAHA.110.205500. Epub 2010 Mar 25.
• [151] Amino acid polymorphisms in the ATP-regulatable inward rectifier Kir6.2 and their relationships to glucose- and tolbutamide-induced insulin secretion, the insulin sensitivity index, and NIDDM. Diabetes. 1997 Mar;46(3):508-12. doi: 10.2337/diab.46.3.508.
• [152] A receptor mechanism for the inhibition of insulin release by epinephrine in man. J Clin Invest. 1967 Jan;46(1):86-94. doi: 10.1172/JCI105514.
• [153] Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999 Jul;34(1):83-8. doi: 10.1161/01.hyp.34.1.83.
• [154] Quinapril treatment restores the vasodilator action of insulin in fructose-hypertensive rats. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):381-5. doi: 10.1046/j.1440-1681.2002.03668.x.
• [155] Retinoic acid can induce markers of endocrine transdifferentiation in pancreatic ductal adenocarcinoma: preliminary observations from an in vitro cell line model. J Clin Pathol. 2006 Jun;59(6):603-10. doi: 10.1136/jcp.2005.032003. Epub 2006 Feb 10.
• [156] Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications. 2005 Jan-Feb;19(1):60-4. doi: 10.1016/j.jdiacomp.2004.05.001.
• [157] Clonidine effect on insulin secretion and lipolysis in man. Acta Diabetol Lat. 1978 May-Aug;15(3-4):192-7. doi: 10.1007/BF02581064.
• [158] Beta-adrenergic contribution to glucagon-induced glucose production and insulin secretion in uremia. Am J Physiol. 1986 Sep;251(3 Pt 1):E322-7. doi: 10.1152/ajpendo.1986.251.3.E322.
• [159] Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res. 1998 Oct;30(10):642-5. doi: 10.1055/s-2007-978950.
• [160] Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cells. J Biochem Mol Toxicol. 2020 Feb;34(2):e22433. doi: 10.1002/jbt.22433. Epub 2020 Jan 9.
• [161] A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations. Toxicol Appl Pharmacol. 2017 Nov 1;334:18-23. doi: 10.1016/j.taap.2017.08.017. Epub 2017 Sep 1.
• [162] CBD Promotes Oral Ulcer Healing via Inhibiting CMPK2-Mediated Inflammasome. J Dent Res. 2022 Feb;101(2):206-215. doi: 10.1177/00220345211024528. Epub 2021 Jul 16.
• [163] Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
• [164] Anti-inflammatory effects of the GABA(B) receptor agonist baclofen in allergic contact dermatitis. Exp Dermatol. 2010 Jul 1;19(7):661-6. doi: 10.1111/j.1600-0625.2010.01076.x. Epub 2010 Feb 25.
• [165] Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways. World J Gastrointest Oncol. 2022 Feb 15;14(2):450-477. doi: 10.4251/wjgo.v14.i2.450.
• [166] Sulfasalazine unveils a contact-independent HSV-TK/ganciclovir gene therapy bystander effect in malignant gliomas. Int J Oncol. 2007 Jan;30(1):283-90.
• [167] Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
• [168] Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
• [169] Quercetin represses apolipoprotein B expression by inhibiting the transcriptional activity of C/EBP. PLoS One. 2015 Apr 15;10(4):e0121784. doi: 10.1371/journal.pone.0121784. eCollection 2015.
• [170] Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. Metabolism. 2004 Jun;53(6):766-71. doi: 10.1016/j.metabol.2003.11.027.
• [171] Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
• [172] Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1336-41. doi: 10.1161/ATVBAHA.109.192088. Epub 2009 Aug 10.
• [173] The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990 Jul;120(1):172-9. doi: 10.1016/0002-8703(90)90175-w.
• [174] Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol. 2002 Apr-Jun;1(2):85-9.
• [175] Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
• [176] Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol Res. 2007 Apr;55(4):310-7. doi: 10.1016/j.phrs.2006.12.009. Epub 2007 Jan 14.
• [177] Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
• [178] Chronic occupational exposure to arsenic induces carcinogenic gene signaling networks and neoplastic transformation in human lung epithelial cells. Toxicol Appl Pharmacol. 2012 Jun 1;261(2):204-16.
• [179] Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.
• [180] Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
• [181] Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor. Mol Cell Biol. 1996 Jul;16(7):3350-60. doi: 10.1128/MCB.16.7.3350.
• [182] Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
• [183] Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity. Cell Biol Toxicol. 2021 Apr;37(2):151-175. doi: 10.1007/s10565-020-09537-1. Epub 2020 Jun 14.
• [184] Linalool is a PPARalpha ligand that reduces plasma TG levels and rewires the hepatic transcriptome and plasma metabolome. J Lipid Res. 2014 Jun;55(6):1098-110.
• [185] C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 3;18(18):2434-7.
• [186] Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
• [187] The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
• [188] Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
• [189] The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):286-97. doi: 10.1185/03007997509114779.
• [190] Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
• [191] Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
• [192] Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 1999 Sep 15;84(6):655-9. doi: 10.1016/s0002-9149(99)00411-7.
• [193] Glucosamine-induced endoplasmic reticulum stress promotes ApoB100 degradation: evidence for Grp78-mediated targeting to proteasomal degradation. Arterioscler Thromb Vasc Biol. 2005 Mar;25(3):571-7. doi: 10.1161/01.ATV.0000154142.61859.94. Epub 2004 Dec 23.
• [194] Aluminum-induced mitochondrial dysfunction leads to lipid accumulation in human hepatocytes: a link to obesity. Cell Physiol Biochem. 2007;20(5):627-38. doi: 10.1159/000107546.
• [195] Insulin-like growth factors (IGF) I and II utilize different calcium signaling pathways in a primary human parathyroid cell culture model. World J Surg. 2006 Mar;30(3):333-45. doi: 10.1007/s00268-005-0339-8.
• [196] Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3). Mol Cell Biochem. 2010 Nov;344(1-2):173-84. doi: 10.1007/s11010-010-0540-4. Epub 2010 Jul 25.
• [197] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [198] Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol. 2005 Aug 10;23(23):5334-46. doi: 10.1200/JCO.2005.03.723. Epub 2005 Jun 6.
• [199] THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
• [200] DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells. Am J Physiol Endocrinol Metab. 2006 May;290(5):E952-60. doi: 10.1152/ajpendo.00451.2005. Epub 2005 Dec 20.
• [201] Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res. 2010 Oct;27(10):2162-74. doi: 10.1007/s11095-010-0219-2. Epub 2010 Jul 29.
• [202] Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
• [203] Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
• [204] Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
• [205] Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
• [206] Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 2007;121(1):59-65. doi: 10.1016/j.thromres.2007.02.001. Epub 2007 Mar 26.
• [207] Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000 Mar;43(3):377-83. doi: 10.1007/s001250050057.
• [208] Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
• [209] ?-adrenoceptors and muscarinic receptors mediate opposing effects on endothelin-1 expression in human lung fibroblasts. Eur J Pharmacol. 2012 Sep 15;691(1-3):218-24. doi: 10.1016/j.ejphar.2012.07.002. Epub 2012 Jul 13.
• [210] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [211] Induction of endothelin-1 expression by oxidative stress in vascular smooth muscle cells. Cardiovasc Pathol. 2001 Nov-Dec;10(6):311-5. doi: 10.1016/s1054-8807(01)00095-3.
• [212] Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
• [213] [Effect of simvastatin on endothelin-1 expression in endothelial cell cultured hypoxically]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Jan;39(1):72-5.
• [214] Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc Nutr Soc. 2008 Feb;67(1):42-7.
• [215] Nucleoside reverse transcriptase inhibitors induce a mitophagy-associated endothelial cytotoxicity that is reversed by coenzyme Q10 cotreatment. Toxicol Sci. 2013 Aug;134(2):323-34. doi: 10.1093/toxsci/kft105. Epub 2013 May 2.
• [216] Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
• [217] Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathway. Mediators Inflamm. 2008;2008:305087. doi: 10.1155/2008/305087. Epub 2008 Dec 1.
• [218] Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun. 2001 Jan 26;280(3):664-74. doi: 10.1006/bbrc.2000.4216.
• [219] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [220] Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
• [221] Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
• [222] CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
• [223] Identification of mechanisms of action of bisphenol a-induced human preadipocyte differentiation by transcriptional profiling. Obesity (Silver Spring). 2014 Nov;22(11):2333-43.
• [224] Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol. 1999 Apr;47(4):433-9. doi: 10.1046/j.1365-2125.1999.00920.x.
• [225] Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to Zidovudine. Environ Mol Mutagen. 2007 Apr-May;48(3-4):179-89. doi: 10.1002/em.20245.
• [226] Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
• [227] Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
• [228] Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
• [229] A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci. 2005 Feb;83(2):282-92.
• [230] In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies. Toxicol Sci. 2007 Sep;99(1):162-73.
• [231] Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
• [232] Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol Sci. 2007 Mar;96(1):101-14.
• [233] The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
• [234] Pharmacological doses of testosterone upregulated androgen receptor and 3-Beta-hydroxysteroid dehydrogenase/delta-5-delta-4 isomerase and impaired leydig cells steroidogenesis in adult rats. Toxicol Sci. 2011 Jun;121(2):397-407. doi: 10.1093/toxsci/kfr063. Epub 2011 Apr 6.
• [235] Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol. 2005 Oct;19(10):2502-16.
• [236] Peroxisome proliferator activated receptor gamma (PPAR-gama) ligand pioglitazone regulated gene networks in term human primary trophoblast cells. Reprod Toxicol. 2018 Oct;81:99-107.
• [237] Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
• [238] The inhibitory effects of manganese on steroidogenesis in rat primary Leydig cells by disrupting steroidogenic acute regulatory (StAR) protein expression. Toxicology. 2003 May 3;187(2-3):139-48. doi: 10.1016/s0300-483x(03)00063-5.
• [239] Endocrine disrupting effects of herbicides and pentachlorophenol: in vitro and in vivo evidence. Environ Sci Technol. 2009 Mar 15;43(6):2144-50. doi: 10.1021/es8028928.
• [240] Chronic senescent human mesenchymal stem cells as possible contributor to the wound healing disorder after exposure to the alkylating agent sulfur mustard. Arch Toxicol. 2021 Feb;95(2):727-747. doi: 10.1007/s00204-020-02946-5. Epub 2021 Jan 25.
• [241] Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep. 2011 Jan;25(1):41-7.
• [242] Troglitazone, a PPARgamma ligand, inhibits osteopontin gene expression in human monocytes/macrophage THP-1 cells. J Atheroscler Thromb. 2000;7(2):77-82. doi: 10.5551/jat1994.7.77.
• [243] Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008 Oct;7(10):1607-18.
• [244] Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
• [245] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [246] Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
• [247] In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist. PPAR Res. 2012;2012:546548. doi: 10.1155/2012/546548. Epub 2012 Oct 22.
• [248] Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
• [249] Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
• [250] Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans. Can J Clin Pharmacol. 1999 Summer;6(2):85-90.
• [251] Regulation of Hepatic Cholesteryl Ester Transfer Protein Expression and Reverse Cholesterol Transport by Inhibition of DNA Topoisomerase II. J Biol Chem. 2015 Jun 5;290(23):14418-29. doi: 10.1074/jbc.M115.643015. Epub 2015 Apr 25.
• [252] Arsenic trioxide suppresses liver X receptor and enhances cholesteryl ester transfer protein expression without affecting the liver X receptor in HepG2 cells. Chem Biol Interact. 2016 Oct 25;258:288-96. doi: 10.1016/j.cbi.2016.09.009. Epub 2016 Sep 10.
• [253] Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells. Int J Mol Med. 2005 Oct;16(4):717-22.
• [254] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [255] Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
• [256] Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
• [257] Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
• [258] Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
• [259] Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 2013 Dec 3;8(12):e82086. doi: 10.1371/journal.pone.0082086. eCollection 2013.
• [260] Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
• [261] Editor's Highlight: Mechanistic Toxicity Tests Based on an Adverse Outcome Pathway Network for Hepatic Steatosis. Toxicol Sci. 2017 Sep 1;159(1):159-169. doi: 10.1093/toxsci/kfx121.
• [262] Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Thromb Res. 2004;113(3-4):197-204. doi: 10.1016/j.thromres.2004.03.002.
• [263] Effect of the Catechol-O-Methyltransferase Inhibitors Tolcapone and Entacapone on Fatty Acid Metabolism in HepaRG Cells. Toxicol Sci. 2018 Aug 1;164(2):477-488.
• [264] Regulation of CD36 expression in human melanoma cells. Adv Exp Med Biol. 2002;507:337-42. doi: 10.1007/978-1-4615-0193-0_52.
• [265] Comparative study of the effects of ziram and disulfiram on human monocyte-derived macrophage functions and polarization: involvement of zinc. Cell Biol Toxicol. 2021 Jun;37(3):379-400. doi: 10.1007/s10565-020-09540-6. Epub 2020 Jul 25.
• [266] Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. Eur J Pharmacol. 2004 Sep 24;499(3):315-24. doi: 10.1016/j.ejphar.2004.07.114.
• [267] Phthalates efficiently bind to human peroxisome proliferator activated receptor and retinoid X receptor , , subtypes: an in silico approach. J Appl Toxicol. 2014 Jul;34(7):754-65. doi: 10.1002/jat.2902. Epub 2013 Jul 11.
• [268] Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium. BMC Genomics. 2004 Aug 20;5(1):58. doi: 10.1186/1471-2164-5-58.
• [269] Identification and characterization of the human retinoid X receptor alpha gene promoter. Gene. 2006 May 10;372:118-27. doi: 10.1016/j.gene.2005.12.027. Epub 2006 Mar 6.
• [270] Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ Health Perspect. 2011 Aug;119(8):1142-8. doi: 10.1289/ehp.1002952. Epub 2011 May 4.
• [271] Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer. Cancer Sci. 2009 Dec;100(12):2459-64.
• [272] Limited Chemical Structural Diversity Found to Modulate Thyroid Hormone Receptor in the Tox21 Chemical Library. Environ Health Perspect. 2019 Sep;127(9):97009. doi: 10.1289/EHP5314. Epub 2019 Sep 30.
• [273] The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem. 2004 Nov 5;279(45):47298-310. doi: 10.1074/jbc.M404101200. Epub 2004 Aug 25.
• [274] [Reversal effect of MDR1 and MDR3 gene silencing on resistance of A2780/taxol cells to paclitaxel]. Zhonghua Fu Chan Ke Za Zhi. 2007 Jun;42(6):412-6.
• [275] 8-Methoxypsoralen disrupts MDR3-mediated phospholipids efflux and bile acid homeostasis and its relevance to hepatotoxicity. Toxicology. 2017 Jul 1;386:40-48. doi: 10.1016/j.tox.2017.05.011. Epub 2017 May 24.
• [276] Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
• [277] Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
• [278] Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2002 May;122(5):339-61.
• [279] Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicity. Toxicol Appl Pharmacol. 2019 Jan 1;362:150-158. doi: 10.1016/j.taap.2018.11.002. Epub 2018 Nov 10.
• [280] The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion. J Biol Chem. 2004 Mar 5;279(10):8856-61. doi: 10.1074/jbc.M306422200. Epub 2003 Dec 18.
• [281] The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol. 2005 Aug;68(2):551-8. doi: 10.1124/mol.105.012104. Epub 2005 May 23.
• [282] Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011 Feb;53(2):548-57. doi: 10.1002/hep.24047. Epub 2010 Dec 10.
• [283] Species-specific mechanisms for cholesterol 7alpha-hydroxylase (CYP7A1) regulation by drugs and bile acids. Arch Biochem Biophys. 2005 Feb 1;434(1):75-85.
• [284] Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
• [285] Activation of the constitutive androstane receptor by monophthalates. Chem Res Toxicol. 2016 Oct 17;29(10):1651-1661.
• [286] All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol. 2010 Jul;150(2):158-69. doi: 10.1111/j.1365-2141.2010.08209.x. Epub 2010 May 9.
• [287] A two-hybrid yeast assay to quantify the effects of xenobiotics on retinoid X receptor-mediated gene expression. Toxicol Lett. 2008 Feb 15;176(3):198-206. doi: 10.1016/j.toxlet.2007.11.006. Epub 2007 Dec 3.
• [288] Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. J Invest Dermatol. 2009 Feb;129(2):329-39. doi: 10.1038/jid.2008.258. Epub 2008 Sep 4.
• [289] Photoaffinity labeling of human retinoid X receptor beta (RXRbeta) with 9-cis-retinoic acid: identification of phytanic acid, docosahexaenoic acid, and lithocholic acid as ligands for RXRbeta. Biochemistry. 2002 Apr 16;41(15):4883-90. doi: 10.1021/bi0121151.
• [290] Gene induction and apoptosis in human hepatocellular carci-noma cells SMMC-7721 exposed to 5-aza-2'-deoxycytidine. Chin Med J (Engl). 2007 Sep 20;120(18):1626-31.
• [291] Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells. Oncol Rep. 2016 Sep;36(3):1233-42. doi: 10.3892/or.2016.4944. Epub 2016 Jul 15.
• [292] Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006 Jan;151(1):139. doi: 10.1016/j.ahj.2005.10.006.
• [293] Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care. 2006 Feb;29(2):195-201. doi: 10.2337/diacare.29.02.06.dc05-1418.
• [294] Repurposing L-menthol for systems medicine and cancer therapeutics? L-menthol induces apoptosis through caspase 10 and by suppressing HSP90. OMICS. 2016 Jan;20(1):53-64.
• [295] Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
• [296] Eptifibatide in peripheral vascular interventions: results of the Integrilin Reduces Inflammation in Peripheral Vascular Interventions (INFLAME) trial. J Invasive Cardiol. 2006 Jan;18(1):6-12.
• [297] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [298] Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia. J Cell Mol Med. 2018 Mar;22(3):1614-1626.
• [299] COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
• [300] The effect of quercetin and kaempferol aglycones and glucuronides on peroxisome proliferator-activated receptor-gamma (PPAR-). Food Funct. 2015 Apr;6(4):1098-107. doi: 10.1039/c5fo00076a.
• [301] Glucosamine sulfate reduces prostaglandin E(2) production in osteoarthritic chondrocytes through inhibition of microsomal PGE synthase-1. J Rheumatol. 2012 Mar;39(3):635-44. doi: 10.3899/jrheum.110621. Epub 2011 Nov 15.
• [302] Isoniazid suppresses antioxidant response element activities and impairs adipogenesis in mouse and human preadipocytes. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):435-41. doi: 10.1016/j.taap.2013.10.005. Epub 2013 Oct 12.
• [303] Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells. Biomed Pharmacother. 2010 Feb;64(2):118-23. doi: 10.1016/j.biopha.2009.04.033. Epub 2009 Oct 17.
• [304] Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients. Antivir Ther. 2003 Aug;8(4):323-31.
• [305] Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther. 2007;12(4):489-500.
• [306] Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol. 2010 Apr 1;140(1):73-81. doi: 10.1016/j.ijcard.2008.11.017. Epub 2008 Dec 6.
• [307] [Quercetin affects leptin and its receptor in human gastric cancer MGC-803 cells and JAK-STAT pathway]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 Jan;28(1):12-6.
• [308] Leptin production in adipocytes from morbidly obese subjects: stimulation by dexamethasone, inhibition with troglitazone, and influence of gender. J Clin Endocrinol Metab. 2000 Aug;85(8):2678-84. doi: 10.1210/jcem.85.8.6733.
• [309] Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. Int J Cardiol. 2009 Mar 20;133(1):23-31. doi: 10.1016/j.ijcard.2007.11.058. Epub 2008 Jan 15.
• [310] The anti-cancer drug gefitinib accelerates Fas-mediated apoptosis by enhancing caspase-8 activation in cancer cells. J Toxicol Sci. 2019;44(6):435-440. doi: 10.2131/jts.44.435.
• [311] NF-B potentiates caspase independent hydrogen peroxide induced cell death. PLoS One. 2011 Feb 15;6(2):e16815. doi: 10.1371/journal.pone.0016815.
• [312] Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells. Oncol Rep. 2011 Feb;25(2):583-91. doi: 10.3892/or.2010.1097. Epub 2010 Dec 10.
• [313] Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
• [314] Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine. Toxicol In Vitro. 2016 Sep;35:66-76. doi: 10.1016/j.tiv.2016.05.013. Epub 2016 May 26.
• [315] Rifampicin inhibits CD95-mediated apoptosis of Jurkat T cells via glucocorticoid receptors by modifying the expression of molecules regulating apoptosis. J Clin Immunol. 2002 Jan;22(1):37-47. doi: 10.1023/a:1014256603539.
• [316] Integrated assessment by multiple gene expression analysis of quercetin bioactivity on anticancer-related mechanisms in colon cancer cells in vitro. Eur J Nutr. 2005 Mar;44(3):143-56. doi: 10.1007/s00394-004-0503-1. Epub 2004 Apr 30.
• [317] Mechanisms of induction of human tissue inhibitor of metalloproteinases-1 (TIMP-1) gene expression by all-trans retinoic acid in combination with basic fibroblast growth factor. Eur J Biochem. 2000 Jul;267(13):4150-6. doi: 10.1046/j.1432-1327.2000.01459.x.
• [318] Cardiac toxicity from ethanol exposure in human-induced pluripotent stem cell-derived cardiomyocytes. Toxicol Sci. 2019 May 1;169(1):280-292.
• [319] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [320] 4-HPR modulates gene expression in ovarian cells. Int J Cancer. 2006 Sep 1;119(5):1005-13. doi: 10.1002/ijc.21797.
• [321] Protein expression profiling identifies molecular targets of quercetin as a major dietary flavonoid in human colon cancer cells. Proteomics. 2004 Jul;4(7):2160-74.
• [322] Positive regulation of hepatic carnitine palmitoyl transferase 1A (CPT1A) activities by soy isoflavones and L-carnitine. Eur J Nutr. 2006 Mar;45(3):159-64. doi: 10.1007/s00394-005-0576-5. Epub 2005 Dec 20.
• [323] Aspirin regulates hepatocellular lipid metabolism by activating AMPK signaling pathway. J Toxicol Sci. 2015 Feb;40(1):127-36. doi: 10.2131/jts.40.127.
• [324] Role of sirtuin 1 in the regulation of hepatic gene expression by thyroid hormone. J Biol Chem. 2013 Jan 11;288(2):807-18. doi: 10.1074/jbc.M112.437970. Epub 2012 Dec 3.
• [325] JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene. 2008 Aug 28;27(37):5033-44.
• [326] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [327] Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr. 2005 Oct;135(10):2305-12. doi: 10.1093/jn/135.10.2305.
• [328] On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis. 2009 Aug;205(2):413-9. doi: 10.1016/j.atherosclerosis.2009.01.008. Epub 2009 Jan 19.
• [329] Gene expression profiling of rheumatoid arthritis synovial cells treated with antirheumatic drugs. J Biomol Screen. 2007 Apr;12(3):328-40. doi: 10.1177/1087057107299261. Epub 2007 Mar 22.
• [330] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [331] Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol. 2010 Apr 15;79(8):1200-9. doi: 10.1016/j.bcp.2009.12.007. Epub 2009 Dec 14.
• [332] Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
• [333] Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
• [334] The potential effects of HECTD4 variants on fasting glucose and triglyceride levels in relation to prevalence of type 2 diabetes based on alcohol intake. Arch Toxicol. 2022 Sep;96(9):2487-2499. doi: 10.1007/s00204-022-03325-y. Epub 2022 Jun 17.
• [335] Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. J Lipid Res. 2004 Nov;45(11):2015-24. doi: 10.1194/jlr.M400049-JLR200. Epub 2004 Aug 16.
• [336] Comparison of the effects of pioglitazone and rosiglitazone on macrophage foam cell formation. Biochem Biophys Res Commun. 2004 Oct 22;323(3):782-8.
• [337] Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice. J Biol Chem. 2014 Aug 8;289(32):22437-49. doi: 10.1074/jbc.M114.548933. Epub 2014 Jul 1.
• [338] Transcriptional Regulation of Human Arylamine N-Acetyltransferase 2 Gene by Glucose and Insulin in Liver Cancer Cell Lines. Toxicol Sci. 2022 Nov 23;190(2):158-172. doi: 10.1093/toxsci/kfac103.
• [339] Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J. 2007 Jun;28(12):1440-7. doi: 10.1093/eurheartj/ehm101. Epub 2007 May 5.
• [340] Adipogenic Effects and Gene Expression Profiling of Firemaster? 550 Components in Human Primary Preadipocytes. Environ Health Perspect. 2017 Sep 14;125(9):097013. doi: 10.1289/EHP1318.
• [341] Combination of an ACE inhibitor and indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J. 2009 Dec;73(12):2282-7. doi: 10.1253/circj.cj-09-0387. Epub 2009 Sep 29.
• [342] Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs. Life Sci. 2020 Jun 15;251:117607. doi: 10.1016/j.lfs.2020.117607. Epub 2020 Mar 30.
• [343] The PPAR gamma agonist troglitazone induces musclin mRNA expression in human myotubes. Horm Metab Res. 2006 Sep;38(9):614-6. doi: 10.1055/s-2006-951310.
• [344] Retinoic acids and trichostatin A (TSA), a histone deacetylase inhibitor, induce human pyruvate dehydrogenase kinase 4 (PDK4) gene expression. Biochim Biophys Acta. 2006 Mar-Apr;1759(3-4):141-51. doi: 10.1016/j.bbaexp.2006.04.005. Epub 2006 Apr 27.
• [345] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [346] Peroxisome Proliferator-activated receptor activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem. 2012 Jul 6;287(28):23667-77. doi: 10.1074/jbc.M112.350181. Epub 2012 May 16.
• [347] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [348] Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011 Dec;21(12):884-93. doi: 10.1097/FPC.0b013e32834d672b.
• [349] Role of multidrug resistance protein 2 (MRP2, ABCC2) in alkylating agent detoxification: MRP2 potentiates glutathione S-transferase A1-1-mediated resistance to chlorambucil cytotoxicity. J Pharmacol Exp Ther. 2004 Jan;308(1):260-7. doi: 10.1124/jpet.103.057729. Epub 2003 Oct 20.
• [350] MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. Int J Cancer. 2005 Sep 20;116(5):824-9. doi: 10.1002/ijc.21013.
• [351] Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
• [352] Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
• [353] In vitro study of transporters involved in intestinal absorption of inorganic arsenic. Chem Res Toxicol. 2012 Feb 20;25(2):446-53. doi: 10.1021/tx200491f. Epub 2012 Jan 26.
• [354] Potency of individual bile acids to regulate bile acid synthesis and transport genes in primary human hepatocyte cultures. Toxicol Sci. 2014 Oct;141(2):538-46. doi: 10.1093/toxsci/kfu151. Epub 2014 Jul 23.
• [355] Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
• [356] Evaluation of drug transporters' significance for multidrug resistance in head and neck squamous cell carcinoma. Head Neck. 2011 Jul;33(7):959-68. doi: 10.1002/hed.21559. Epub 2010 Aug 24.
• [357] Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
• [358] Epidermal growth factor receptor signalling in human breast cancer cells operates parallel to estrogen receptor alpha signalling and results in tamoxifen insensitive proliferation. BMC Cancer. 2014 Apr 23;14:283.
• [359] Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3. Diabetes. 2012 Apr;61(4):797-806. doi: 10.2337/db11-0846. Epub 2012 Feb 14.
• [360] Thiazolidinediones are potent inducers of fibroblast growth factor 21 expression in the liver. Biol Pharm Bull. 2011;34(7):1120-1. doi: 10.1248/bpb.34.1120.
• [361] Activation of GR but not PXR by dexamethasone attenuated acetaminophen hepatotoxicities via Fgf21 induction. Toxicology. 2017 Mar 1;378:95-106. doi: 10.1016/j.tox.2017.01.009. Epub 2017 Jan 11.
• [362] Increased immunoreactivity and concentration of basic fibroblast growth factor in lansoprazole-treated gastric mucosa. J Clin Gastroenterol. 1995;21 Suppl 1:S24-9.
• [363] Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
• [364] Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology. 2014 Feb;146(2):539-49.e7. doi: 10.1053/j.gastro.2013.10.059. Epub 2013 Nov 1.
• [365] Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
• [366] ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther. 2004 Aug;9(4):519-28.
• [367] Selenium-dependent and -independent transport of arsenic by the human multidrug resistance protein 2 (MRP2/ABCC2): implications for the mutual detoxification of arsenic and selenium. Carcinogenesis. 2010 Aug;31(8):1450-5. doi: 10.1093/carcin/bgq125. Epub 2010 Jun 27.
• [368] Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. Int J Cancer. 2009 May 15;124(10):2303-11. doi: 10.1002/ijc.24207.
• [369] Prolonged use of aspirin alters human and rat intestinal cells and thereby limits the absorption of clopidogrel. Clin Pharmacol Ther. 2011 Oct;90(4):612-9. doi: 10.1038/clpt.2011.163. Epub 2011 Sep 7.